WearLinq

The eWave 6-lead ECG monitor holds FDA clearance as a wireless, continuous, multimodal cardiac monitoring device. The company markets it specifically as the first FDA-cleared wireless continuous 6-lead ECG multimodal monitor. The clearance covers ambulatory monitoring applications including Extended Holter modalities.

WearLinq's LiveLinq platform provides clinicians with full-disclosure access to the entire patient ECG study. The system delivers all waveform data — not just triggered episodes — and supports configurable display layouts and a zoom feature for detailed signal-level analysis. The platform is designed for use across all monitoring modalities, including Extended Holter, and generates STAT reports on a daily basis.

The eWave captures six distinct ECG leads rather than a single lead, which the company states provides six times the diagnostic visibility. This multi-lead configuration gives clinicians a multidimensional view of cardiac activity, enabling more detailed interpretation of rhythm abnormalities and ischemic changes that a single-lead patch would miss. The device is also the lightest ECG monitor on the market, a design factor intended to improve patient compliance during continuous wear.

WearLinq is headquartered in San Francisco, California. The company markets its eWave device in the United States, where it holds FDA clearance. The firm has not publicly disclosed international regulatory approvals or commercial operations outside the US market.

WearLinq has not publicly disclosed its venture funding history, total capital raised, or institutional investors. The firm operates as a private company and does not list financial backers on its website or in publicly available materials as of early 2026.